Interstitial Cystitis Clinical Trial
Official title:
Prospective Randomized Controlled Trial Comparing the Effect of Fulguration Versus Fulguration and Hydrodistension in Interstitial Cystitis/Bladder Pain Syndrome
Verified date | August 2019 |
Source | Yonsei University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a randomized controlled trial. Subject population is adult patients with Hunner-type interstitial cystitis. The objective of this study is to compare the therapeutic effect between the two surgical modality; TUF (transurethral fulguration of the Hunner lesion) versus TUF+HD(addition of bladder hydrodistension prior to transurethral fulguration of the Hunner lesion).
Status | Completed |
Enrollment | 55 |
Est. completion date | October 31, 2018 |
Est. primary completion date | October 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 29 Years to 83 Years |
Eligibility |
Inclusion Criteria: - 1. cystoscopically proven Hunner lesion, without other demonstrable lower urinary tract diseases - 2. Adult patient aged more than 19 years - 3. Duration of IC/BPS symptom of more than 6 months - 4. VAS pain score more than point 4 (including point 4) - 5. The total score of O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) symptom and problem is more than 12 with the score of pain item is more than 2 - 6. The total score of Pelvic pain urgency/frequency patient symptom scale more than point 13 Exclusion Criteria: - 1. Patient with history of bladder hydrodistension or transurethral fulguration within the period of 3 months - 2. Women patients who are likely to become pregnant - 3. Patients with average voided volume more than 400ml - 4. Patients with hematuria suspicious of malignancy - 5. Patients with microbiologically proven urinary tract infection during the screening period - 6. Patients with microbiologically proven recurrent urinary tract infection, more than twice during the last 6 months or more than three times of infection during the last year - 7. Patients with previous history of genitourinary tuberculosis - 8. Patients with previous history of genitourinary malignancy - 9. Patients with previous history of bladder augmentation - 10. Patient with following surgery within recent 6 months at screening; hysterectomy, midureteral or suburethral sling operation, transvaginal operation, pelvic organ prolapse surgery, vaginal delivery, Caesarean section, prostate surgery, and any other treatment that might affect bladder sensation and bladder function. - 11. Patients with neurological diseases which might affect bladder function - 12. patients who rely on assisted emptying ; like clean intermittent catheterization or indwelling catheterization - 13. patients who are planning to rehabilitation treatment affect the bladder function, like intravesical electronic stimulation - 14. patient with alcohol or drug addiction - 15. any patient who are not fit for the study based on the investigator's decision |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Department of Urology and Urological Science Institute, Yonsei University College of Medicine | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University | Ewha Womans University Mokdong Hospital |
Korea, Republic of,
Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Extent of Hunner lesions: The relationships with symptom severity and clinical parameters in Hunner type interstitial cystitis patients. Neurourol Urodyn. 2018 Apr;37(4):1441-1447. doi: 10.1002/nau.23467. Epub 2018 Jan 9. — View Citation
Bosch PC. A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. Eur Urol. 2018 Nov;74(5):623-630. doi: 10.1016/j.eururo.2018.07.026. Epub 2018 Jul 30. — View Citation
Kirk PS, Santiago-Lastra Y, Qin Y, Stoffel JT, Clemens JQ, Cameron AP. The effects of cystoscopy and hydrodistention on symptoms and bladder capacity in interstitial cystitis/bladder pain syndrome. Neurourol Urodyn. 2018 Aug;37(6):2002-2007. doi: 10.1002/nau.23555. Epub 2018 Mar 22. — View Citation
Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018 Nov;122(5):729-743. doi: 10.1111/bju.14399. Epub 2018 Jun 13. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | inter-group difference of VAS pain score at postoperative one month | Primary end-point is inter-group difference of VAS pain score at postoperative one month. Analysis is performed based on independent two sample t-test. ; About the VAS pain score -'VAS' is abbreviation of 'Visual Analogue Scale'. For evaluation of pain, we use 'Visual Analogue Scale' which has a range from 0 to 10 points. The score increases depending on the severity of the pain symptoms. |
at postoperative one month | |
Secondary | inter-group differences in drop-out rate at postoperative 6 months | Assessment of Drop-out rate is performed at the point of postoperative 6 months (both using the Intention-To-Treat and Per-Protocol analysis) | at postoperative 6 months | |
Secondary | inter-group differences in O'Leary-Sant Interstitial Cystitis-Questionnaires | O'Leary-Sant questionnaire assesses severity of symptoms on the bladder pain, frequency, urgency, nocturia, composed of symptom index and problem index | at postoperative 1 month | |
Secondary | inter-group differences in O'Leary-Sant Interstitial Cystitis-Questionnaires | O'Leary-Sant questionnaire assesses severity of symptoms on the bladder pain, frequency, urgency, nocturia, composed of symptom index and problem index | at postoperative 2 months | |
Secondary | inter-group differences in O'Leary-Sant Interstitial Cystitis-Questionnaires | O'Leary-Sant questionnaire assesses severity of symptoms on the bladder pain, frequency, urgency, nocturia, composed of symptom index and problem index | at postoperative 4 months | |
Secondary | inter-group differences in O'Leary-Sant Interstitial Cystitis-Questionnaires | O'Leary-Sant questionnaire assesses severity of symptoms on the bladder pain, frequency, urgency, nocturia, composed of symptom index and problem index | at postoperative 6 months | |
Secondary | inter-group differences in PUF(Pelvic pain and Urgency/Frequency patient symptom scale) | PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is questionnaire which evaluates symptoms of pain, urgency, and frequency and how much they bother the patient. PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is composed of two compartment; symptom score (7 items) and bother score (4 items). The symptom scores range from 2~23 points and the symptom scores range from 0~12 points. The higher the score, the worse the symptoms. | at postoperative 1 month | |
Secondary | inter-group differences in PUF(Pelvic pain and Urgency/Frequency patient symptom scale) | PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is questionnaire which evaluates symptoms of pain, urgency, and frequency and how much they bother the patient. PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is composed of two compartment; symptom score (7 items) and bother score (4 items). The symptom scores range from 2~23 points and the symptom scores range from 0~12 points. The higher the score, the worse the symptoms. | at postoperative 2 months | |
Secondary | inter-group differences in PUF(Pelvic pain and Urgency/Frequency patient symptom scale) | PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is questionnaire which evaluates symptoms of pain, urgency, and frequency and how much they bother the patient. PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is composed of two compartment; symptom score (7 items) and bother score (4 items). The symptom scores range from 2~23 points and the symptom scores range from 0~12 points. The higher the score, the worse the symptoms. | at postoperative 4 months | |
Secondary | inter-group differences in PUF(Pelvic pain and Urgency/Frequency patient symptom scale) | PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is questionnaire which evaluates symptoms of pain, urgency, and frequency and how much they bother the patient. PUF (Pelvic pain and Urgency/Frequency patient symptom scale) is composed of two compartment; symptom score (7 items) and bother score (4 items). The symptom scores range from 2~23 points and the symptom scores range from 0~12 points. The higher the score, the worse the symptoms. | at postoperative 6 months | |
Secondary | inter-group differences in EQ-5D Health Questionnaire | The EQ-5D questionnaire is a tool for brief evaluation of subject's health status. The EQ-5D questionnaire has five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has three-level; having no problems, having some or moderate problems, being unable to do/having extreme problems. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number. The 5-digit number is finally converted to a single summary index by a specific formula. | at postoperative 1 month | |
Secondary | inter-group differences in EQ-5D Health Questionnaire | The EQ-5D questionnaire is a tool for brief evaluation of subject's health status. The EQ-5D questionnaire has five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has three-level; having no problems, having some or moderate problems, being unable to do/having extreme problems. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number. The 5-digit number is finally converted to a single summary index by a specific formula. | at postoperative 2 months | |
Secondary | inter-group differences in EQ-5D Health Questionnaire | The EQ-5D questionnaire is a tool for brief evaluation of subject's health status. The EQ-5D questionnaire has five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has three-level; having no problems, having some or moderate problems, being unable to do/having extreme problems. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number. The 5-digit number is finally converted to a single summary index by a specific formula. | at postoperative 4 months | |
Secondary | inter-group differences in EQ-5D Health Questionnaire | The EQ-5D questionnaire is a tool for brief evaluation of subject's health status. The EQ-5D questionnaire has five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has three-level; having no problems, having some or moderate problems, being unable to do/having extreme problems. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number. The 5-digit number is finally converted to a single summary index by a specific formula. | at postoperative 6 months | |
Secondary | Brief Pain Inventory-short form (BPI-sf) | Brief Pain Inventory-short form (BPI-sf) is composed of two domains measured by the "pain severity" and the "pain interference", Pain severity compartment is composed of 4 items, and pain interference compartment is composed of 7 items (of 24-hour recall period). Each item has 0-10 scales. Brief pain severity score is calculated by adding the scores of 4 questions and then dividing by 4. Brief pain interference score is calculated by adding the scores for 7 questions and then dividing by 7. | at postoperative 1 month | |
Secondary | Brief Pain Inventory-short form (BPI-sf) | Brief Pain Inventory-short form (BPI-sf) is composed of two domains measured by the "pain severity" and the "pain interference", Pain severity compartment is composed of 4 items, and pain interference compartment is composed of 7 items (of 24-hour recall period). Each item has 0-10 scales. Brief pain severity score is calculated by adding the scores of 4 questions and then dividing by 4. Brief pain interference score is calculated by adding the scores for 7 questions and then dividing by 7. | at postoperative 2 months | |
Secondary | Brief Pain Inventory-short form (BPI-sf) | Brief Pain Inventory-short form (BPI-sf) is composed of two domains measured by the "pain severity" and the "pain interference", Pain severity compartment is composed of 4 items, and pain interference compartment is composed of 7 items (of 24-hour recall period). Each item has 0-10 scales. Brief pain severity score is calculated by adding the scores of 4 questions and then dividing by 4. Brief pain interference score is calculated by adding the scores for 7 questions and then dividing by 7. | at postoperative 4 months | |
Secondary | Brief Pain Inventory-short form (BPI-sf) | Brief Pain Inventory-short form (BPI-sf) is composed of two domains measured by the "pain severity" and the "pain interference", Pain severity compartment is composed of 4 items, and pain interference compartment is composed of 7 items (of 24-hour recall period). Each item has 0-10 scales. Brief pain severity score is calculated by adding the scores of 4 questions and then dividing by 4. Brief pain interference score is calculated by adding the scores for 7 questions and then dividing by 7. | at postoperative 6 months | |
Secondary | Patient Global Assessment (PGA) | Patient Global Assessment (PGA) is composed of a single questionnaire assessing the subjective patients-reported outcome. The question is "How is your bladder condition today?". The patients choose one of the following five answers; very-good, god, moderate, bad, very bad. | at postoperative 1 month | |
Secondary | Patient Global Assessment (PGA) | Patient Global Assessment (PGA) is composed of a single questionnaire assessing the subjective patients-reported outcome. The question is "How is your bladder condition today?". The patients choose one of the following five answers; very-good, god, moderate, bad, very bad. | at postoperative 2 months | |
Secondary | Patient Global Assessment (PGA) | Patient Global Assessment (PGA) is composed of a single questionnaire assessing the subjective patients-reported outcome. The question is "How is your bladder condition today?". The patients choose one of the following five answers; very-good, god, moderate, bad, very bad. | at postoperative 4 months | |
Secondary | Patient Global Assessment (PGA) | Patient Global Assessment (PGA) is composed of a single questionnaire assessing the subjective patients-reported outcome. The question is "How is your bladder condition today?". The patients choose one of the following five answers; very-good, god, moderate, bad, very bad. | at postoperative 6 months | |
Secondary | frequency volume chart parameters | frequency volume chart is a tool for assessment of micturition time, volume of urination and urgency episode. 24-hr frequency of micturition, maximum voided volume, episode of urgency, and nocturia is evaluated. | at postoperative 1 month | |
Secondary | frequency volume chart parameters | frequency volume chart is a tool for assessment of micturition time, volume of urination and urgency episode. 24-hr frequency of micturition, maximum voided volume, episode of urgency, and nocturia is evaluated. | at postoperative 2 months | |
Secondary | frequency volume chart parameters | frequency volume chart is a tool for assessment of micturition time, volume of urination and urgency episode. 24-hr frequency of micturition, maximum voided volume, episode of urgency, and nocturia is evaluated. | at postoperative 4 months | |
Secondary | frequency volume chart parameters | frequency volume chart is a tool for assessment of micturition time, volume of urination and urgency episode. 24-hr frequency of micturition, maximum voided volume, episode of urgency, and nocturia is evaluated. | at postoperative 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Completed |
NCT03282318 -
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT03463499 -
The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients
|
N/A | |
Completed |
NCT02898220 -
Trans-MAPP II Study of Urologic Chronic Pelvin Pain
|
||
Terminated |
NCT02591199 -
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT02247557 -
Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis
|
Phase 2 | |
Active, not recruiting |
NCT01731470 -
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
|
N/A | |
Completed |
NCT01197261 -
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
|
Phase 2 | |
Completed |
NCT00971568 -
Urinary Biomarkers Characteristic to Interstitial Cystitis
|
N/A | |
Completed |
NCT00527917 -
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
|
Phase 2 | |
Completed |
NCT00150488 -
URACYST® For the Treatment of GAG Deficient Interstitial Cystitis
|
N/A | |
Recruiting |
NCT00094874 -
Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms
|
Phase 3 | |
Terminated |
NCT00086684 -
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
|
Phase 4 | |
Recruiting |
NCT04845217 -
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT04401176 -
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT05147779 -
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
|
Phase 1 | |
Suspended |
NCT04450316 -
Low-dose Naltrexone for Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04010513 -
Hypnosis for Bladder Pain Syndrome
|
N/A | |
Completed |
NCT05179460 -
A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
|
||
Completed |
NCT02232282 -
Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial
|
N/A |